Larson Financial Group’s Outlook Therapeutics OTLK Stock Holding History

Larson Financial Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21	Hold	100	–	–	﹤0.01%	3582
2025 Q4	$158	Hold	100	–	–	﹤0.01%	3306
2025 Q3	$106	Hold	100	–	–	﹤0.01%	3322
2025 Q2	$160	Hold	100	–	–	﹤0.01%	3097
2025 Q1	$122	Hold	100	–	–	﹤0.01%	2881
2024 Q4	$189	Hold	100	–	–	﹤0.01%	2456
2024 Q3	$534	Hold	100	–	–	﹤0.01%	2111
2024 Q2	$738	Hold	100	–	–	﹤0.01%	1769
2024 Q1	$1.19K	Hold	100	–	–	﹤0.01%	1427
2023 Q4	$788	Hold	100	–	–	﹤0.01%	1510
2023 Q3	$442	Hold	100	–	–	﹤0.01%	1587
2023 Q2	$3.48K	Hold	100	–	–	﹤0.01%	1171
2023 Q1	$2.18K	Hold	100	–	–	﹤0.01%	1231
2022 Q4	$2.16K	Buy	+100	New	+$2.17K	﹤0.01%	1181

Other funds holding OTLK

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $126M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NMC

Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Larson Financial Group's OTLK Position: Q1 2026 in Review

Larson Financial Group held its Outlook Therapeutics (OTLK) position steady in Q1 2026 at 100 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #3582.

Larson Financial Group first reported a position in OTLK in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.48K in Q2 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

Larson Financial Group held 100 shares of Outlook Therapeutics worth $21 as of Q1 2026.
Larson Financial Group left its Outlook Therapeutics share count unchanged in Q1 2026.
Outlook Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3582 holding.
Larson Financial Group first reported a position in Outlook Therapeutics in Q4 2022 and has held it in 14 quarters since.
Larson Financial Group's Outlook Therapeutics position peaked at $3.48K in Q2 2023.
54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.